The BeyondSpring Pharmaceuticals CEO Dr. Lan Huang talks through receiving U.S. FDA and China NMPA acceptance of its new drug application with priority review for use of its lead product Plinabulin. Huang says early clinical data supports Plinabulin as a direct anti-cancer agent in combination with PD1/PDL1 inhibitors in small cell lung cancer.
15 Jun 2021
The Watch List
28 Apr 2022
The Watch List
20 Apr 2022
Morning Trade Live
18 Mar 2022
Trading 360
18 Apr 2022
Market On Close
05 Apr 2022
The Watch List
20 May 2022